50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.30 (-0.26%)
META   136.37 (-2.88%)
GOOGL   98.14 (-0.61%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.87 (-2.46%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.14 (-3.25%)
PFE   43.83 (-0.57%)
NFLX   223.95 (-1.09%)
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.30 (-0.26%)
META   136.37 (-2.88%)
GOOGL   98.14 (-0.61%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.87 (-2.46%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.14 (-3.25%)
PFE   43.83 (-0.57%)
NFLX   223.95 (-1.09%)
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.30 (-0.26%)
META   136.37 (-2.88%)
GOOGL   98.14 (-0.61%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.87 (-2.46%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.14 (-3.25%)
PFE   43.83 (-0.57%)
NFLX   223.95 (-1.09%)
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.30 (-0.26%)
META   136.37 (-2.88%)
GOOGL   98.14 (-0.61%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.87 (-2.46%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.14 (-3.25%)
PFE   43.83 (-0.57%)
NFLX   223.95 (-1.09%)
NASDAQ:KZIA

Kazia Therapeutics - KZIA Stock Forecast, Price & News

$1.17
+0.04 (+3.54%)
(As of 09/26/2022 04:27 PM ET)
Add
Compare
Today's Range
$1.14
$1.21
50-Day Range
$1.13
$3.85
52-Week Range
$1.04
$12.28
Volume
14,786 shs
Average Volume
238,630 shs
Market Capitalization
$15.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

Kazia Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1,438.5% Upside
$18.00 Price Target
Short Interest
Healthy
1.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.56 out of 5 stars

Medical Sector

982nd out of 1,069 stocks

Pharmaceutical Preparations Industry

482nd out of 533 stocks

KZIA stock logo

About Kazia Therapeutics (NASDAQ:KZIA) Stock

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Receive KZIA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KZIA Stock News Headlines

See More Headlines
Receive KZIA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KZIA Company Calendar

Today
9/26/2022
Next Earnings (Estimated)
12/01/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KZIA
Employees
2,021
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.00
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+1,438.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$20,000.00
Book Value
$1.02 per share

Miscellaneous

Free Float
13,072,000
Market Cap
$15.45 million
Optionable
Not Optionable
Beta
2.43

Key Executives

  • Dr. James Garner M.A.I.C.D. (Age 49)
    M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (, CEO, MD & Exec. Director
    Comp: $634.52k
  • Ms. Gabrielle Heaton BBUS (ACC)
    CPA, Director of Fin. & Admin.
  • Ms. Catherine Jane Hill ACA (Age 63)
    B.Sc., BSc (Hons), C.A., GAICD, Company Sec.
    Comp: $94.71k
  • Ms. Karen R. Krumeich (Age 68)
    Chief Financial Officer
  • Dr. John E. Friend II (Age 52)
    M.D., Chief Medical Officer













KZIA Stock - Frequently Asked Questions

Should I buy or sell Kazia Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kazia Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KZIA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KZIA, but not buy additional shares or sell existing shares.
View KZIA analyst ratings
or view top-rated stocks.

What is Kazia Therapeutics' stock price forecast for 2022?

2 Wall Street research analysts have issued 12 month target prices for Kazia Therapeutics' stock. Their KZIA share price forecasts range from $18.00 to $18.00. On average, they expect the company's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 1,492.9% from the stock's current price.
View analysts price targets for KZIA
or view top-rated stocks among Wall Street analysts.

How have KZIA shares performed in 2022?

Kazia Therapeutics' stock was trading at $8.42 at the beginning of 2022. Since then, KZIA stock has decreased by 86.6% and is now trading at $1.13.
View the best growth stocks for 2022 here
.

When is Kazia Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, December 1st 2022.
View our KZIA earnings forecast
.

What other stocks do shareholders of Kazia Therapeutics own?
What is Kazia Therapeutics' stock symbol?

Kazia Therapeutics trades on the NASDAQ under the ticker symbol "KZIA."

Who are Kazia Therapeutics' major shareholders?

Kazia Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include SG Americas Securities LLC (0.11%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Kazia Therapeutics?

Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kazia Therapeutics' stock price today?

One share of KZIA stock can currently be purchased for approximately $1.13.

How much money does Kazia Therapeutics make?

Kazia Therapeutics (NASDAQ:KZIA) has a market capitalization of $14.92 million and generates $20,000.00 in revenue each year.

How many employees does Kazia Therapeutics have?

The company employs 2,021 workers across the globe.

How can I contact Kazia Therapeutics?

Kazia Therapeutics' mailing address is Three International Towers Level 24 300 Barangaroo Avenue, Sydney C3, 2000. The official website for the company is www.kaziatherapeutics.com. The company can be reached via phone at (129) 472-4101, via email at investment.consultant@novogen.com, or via fax at 61-2-9476-0388.

This page (NASDAQ:KZIA) was last updated on 9/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.